An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Astria Therapeutics to Present at Upcoming Wedbush PacGrow Healthcare Conference 2022
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Astria Therapeutics, Inc. (NASDAQ:ATXS) announced that CEO Jill C. Milne, Ph.D., will present a corporate overview at the Wedbush PacGrow Healthcare Conference on August 10 at 9:10 AM ET. The focus will be on STAR-0215, an innovative therapy for hereditary angioedema in preclinical development. Attendees can access the live webcast here, with a replay available for 30 days on their website. Astria is dedicated to developing therapies for rare allergic and immunological diseases.
Positive
None.
Negative
None.
BOSTON--(BUSINESS WIRE)--
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the upcoming virtual Wedbush PacGrow Healthcare Conference on Wednesday, August 10, at 9:10am ET.
A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/wedbush42/atxs/2256640. An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.
What is Astria Therapeutics presenting at the Wedbush PacGrow Healthcare Conference?
Astria Therapeutics will present a corporate overview and information about their lead program, STAR-0215, at the Wedbush PacGrow Healthcare Conference on August 10 at 9:10 AM ET.
When is the Wedbush PacGrow Healthcare Conference where ATXS will present?
The Wedbush PacGrow Healthcare Conference is on August 10, 2022, at 9:10 AM ET.
How can I access the Astria Therapeutics presentation?
You can access the live webcast of Astria Therapeutics' presentation at the Wedbush PacGrow Healthcare Conference here.
What is STAR-0215 developed by Astria Therapeutics?
STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for treating hereditary angioedema.
